Recent clinical and preclinical research showcases novel treatment developments. A South Korean biotech disclosed promising MASH trial results for its dual GLP-1/glucagon receptor agonist with notable reductions in liver fat and weight. Novoviah Pharmaceuticals introduced a blood-based T cell reactivity assay to detect celiac disease with high sensitivity and specificity, improving upon cumbersome traditional diagnosis. Ileadbms reported positive preclinical data for CXCR7 agonists targeting rheumatoid arthritis inflammation. Meanwhile, pharmaceutical developments target B cell depletion therapies effective against autoimmune disorders like lupus and rheumatoid arthritis.